Ghannoum M A, Spellberg B J, Ibrahim A S, Ritchie J A, Currie B, Spitzer E D, Edwards J E, Casadevall A
Department of Medicine, Harbor-University of California, Los Angeles Medical Center, Torrance 90509.
Antimicrob Agents Chemother. 1994 Sep;38(9):2029-33. doi: 10.1128/AAC.38.9.2029.
Analysis of the sterol compositions of 13 clinical isolates of the pathogenic yeast Cryptococcus neoformans obtained from five patients with recurring cryptococcal meningitis showed that, unlike Candida albicans, the major sterols synthesized by this yeast were obtusifoliol (range, 21.1 to 68.2%) and ergosterol (range, 0.0 to 46.5%). There was considerable variation in the sterol contents among the 13 isolates, with total sterol contents ranging from 0.31 to 5.9% of dry weight. The isolates from the five patients who had relapses had different total sterol contents and compositions in comparison with those of the pretreatment isolates, indicating either that the sterols had been changed by therapy or that the patients were infected with new isolates with different sterol compositions. Growth of the cryptococcal isolates in the presence of subinhibitory concentrations of fluconazole (0.25x the MIC) significantly altered the sterol content and pattern. The total sterol content decreased in nine isolates and increased in four isolates in response to pretreatment with fluconazole. Fluconazole had no consistent effect on ergosterol levels. In contrast, fluconazole caused a decrease in obtusifoliol levels and an increase in 4,14-dimethylzymosterol levels in all isolates. These results indicate extensive diversity in sterol content, sterol composition, and sterol synthesis in response to subinhibitory concentrations of fluconazole in C. neoformans strains. We propose that fluconazole inhibits the sterol synthesis of C. neoformans by interfering with both 14 alpha-demethylase-dependent and -independent pathways. No correlation between the sterol compositions of C. neoformans isolates and their susceptibilities to fluconazole was found.
对从5例复发性隐球菌性脑膜炎患者中分离出的13株致病性酵母新型隐球菌的甾醇成分分析表明,与白色念珠菌不同,该酵母合成的主要甾醇为钝叶醇(范围为21.1%至68.2%)和麦角甾醇(范围为0.0%至46.5%)。13株分离株的甾醇含量存在相当大的差异,总甾醇含量占干重的0.31%至5.9%。与治疗前的分离株相比,5例复发患者的分离株具有不同的总甾醇含量和组成,这表明甾醇可能因治疗而发生了变化,或者患者感染了具有不同甾醇组成的新分离株。在亚抑制浓度的氟康唑(0.25倍MIC)存在下,隐球菌分离株的生长显著改变了甾醇含量和模式。用氟康唑预处理后,9株分离株的总甾醇含量降低,4株分离株的总甾醇含量增加。氟康唑对麦角甾醇水平没有一致的影响。相反,氟康唑使所有分离株中的钝叶醇水平降低,4,14 - 二甲基酵母甾醇水平升高。这些结果表明,新型隐球菌菌株在对亚抑制浓度氟康唑的反应中,甾醇含量、甾醇组成和甾醇合成存在广泛的多样性。我们认为氟康唑通过干扰14α - 脱甲基酶依赖性和非依赖性途径来抑制新型隐球菌的甾醇合成。未发现新型隐球菌分离株的甾醇组成与其对氟康唑的敏感性之间存在相关性。